On 9/30/19, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) stock suffered a major decline of -12.4%, closing at $3.01. Moreover, this decline was accompanied by above average trading volume at 124% of normal. Relative to the market the stock has been extremely weak over the last nine months and has declined -15.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be below the cost of capital, LXRX is expected to be a major Value Eraser.
LXRX is currently unrated.
The stock is currently unrated.